“Recent evidence supports involvement of amylin and the amylin receptor in the pathogenesis of Alzheimer’s disease (AD). We have previously shown that amylin receptor antagonist, AC253, improves spatial memory in AD mouse models. Herein, we generated and screened a peptide library and identified two short sequence amylin peptides (12–14 aa) that are proteolytically stable, brain penetrant when administered intraperitoneally, neuroprotective against Aβ toxicity and restore diminished levels of hippocampal long term potentiation in AD mice.”
More on Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model (2019) by Soudi et al. via Nature Scientific Reports.
UBC Family Practice Residency Program: Abbotsford-Mission Site 